Ind-Ra has reviewed fund-based limits worth Rs550 crore, which has been enhanced from Rs440 crore.
Company’s non-fund-based facilities reviewed are worth Rs1,135 crore.
Ind-Ra maintains a consolidated perspective of JVL and its wholly-owned subsidiaries: Jubilant Infrastructure Limited (‘IND A-‘/Stable), Jubilant Lifesciences International Pte. Ltd, Jubilant Lifesciences NV, Jubilant Lifesciences USA Inc., and Jubilant Lifesciences International Pte. Ltd., and others.
The improvement reflects consistent operating performance and deleveraging, which will result in improved credit metrics in FY22. Given its strong market position in its major products internationally, Ind-Ra has recognised JVL’s capacity to successfully pass on rising input and energy prices, despite a lag.
At around 11.38 AM, Jubilant Ingrevia was trading at Rs504, up by 0.64% against previous close of Rs500.80 on NSE. The scrip touched intraday high and low of Rs517.10 and Rs492.10 respectively, so far.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.